| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Roger G Pertwe. Elevating endocannabinoid levels: pharmacological strategies and potential therapeutic applications. The Proceedings of the Nutrition Society. vol 73. issue 1. 2014-09-24. PMID:24135210. |
the endocannabinoid system consists of cannabinoid cb1 and cb2 receptors, of endogenous agonists for these receptors known as 'endocannabinoids', and of processes responsible for endocannabinoid biosynthesis, cellular uptake and metabolism. |
2014-09-24 |
2023-08-12 |
Not clear |
| Francisco León, Jiangtao Gao, Olivia R Dale, Yunshan Wu, Eman Habib, Afeef S Husni, Robert A Hill, Stephen J Cutle. Secondary metabolites from Eupenicillium parvum and their in vitro binding affinity for human opioid and cannabinoid receptors. Planta medica. vol 79. issue 18. 2014-09-23. PMID:24288291. |
several isolated compounds were evaluated for in vitro binding assays using opioid receptors (subtypes δ, κ, and µ) and cannabinoid receptors (cb1 and cb2). |
2014-09-23 |
2023-08-12 |
human |
| Tomohiro Kimura, Krishna Vukoti, Diane L Lynch, Dow P Hurst, Alan Grossfield, Michael C Pitman, Patricia H Reggio, Alexei A Yeliseev, Klaus Gawrisc. Global fold of human cannabinoid type 2 receptor probed by solid-state 13C-, 15N-MAS NMR and molecular dynamics simulations. Proteins. vol 82. issue 3. 2014-09-19. PMID:23999926. |
the global fold of human cannabinoid type 2 (cb2 ) receptor in the agonist-bound active state in lipid bilayers was investigated by solid-state (13)c- and (15)n magic-angle spinning (mas) nmr, in combination with chemical-shift prediction from a structural model of the receptor obtained by microsecond-long molecular dynamics (md) simulations. |
2014-09-19 |
2023-08-12 |
human |
| Ulrike Thieme, Gustav Schelling, Daniela Hauer, Robert Greif, Torsten Dame, Ruediger Paul Laubender, Werner Bernhard, Detlef Thieme, Patrizia Campolongo, Lorenz Theile. Quantification of anandamide and 2-arachidonoylglycerol plasma levels to examine potential influences of tetrahydrocannabinol application on the endocannabinoid system in humans. Drug testing and analysis. vol 6. issue 1-2. 2014-09-15. PMID:24424856. |
the effects of tetrahydrocannabinol (thc) and endogenous cannabinoids (endocannabinoids, ecs) are both mediated by activation of the cannabinoid receptors cb1 and cb2. |
2014-09-15 |
2023-08-12 |
human |
| Guoqiang Xing, Janis Carlton, Xiaolong Jiang, Jillian Wen, Min Jia, He L. Differential Expression of Brain Cannabinoid Receptors between Repeatedly Stressed Males and Females may Play a Role in Age and Gender-Related Difference in Traumatic Brain Injury: Implications from Animal Studies. Frontiers in neurology. vol 5. 2014-09-15. PMID:25221540. |
because females are more likely to develop anxiety after stress and because anxiety is mediated by cannabinoid receptors (cbrs) (cb1 and cb2), there is a need to compare cb1 and cb2 expression in stressed males and females. |
2014-09-15 |
2023-08-13 |
rat |
| Francesca Rossi, Maria Ester Bernardo, Giulia Bellini, Livio Luongo, Antonella Conforti, Iolanda Manzo, Francesca Guida, Luigia Cristino, Roberta Imperatore, Stefania Petrosino, Bruno Nobili, Vincenzo Di Marzo, Franco Locatelli, Sabatino Maion. The cannabinoid receptor type 2 as mediator of mesenchymal stromal cell immunosuppressive properties. PloS one. vol 8. issue 11. 2014-09-11. PMID:24312195. |
we show, for the first time, that cultures of human mesenchymal stromal cells express all of the components of the endocannabinoid system, suggesting a potential role for the cannabinoid cb2 receptor as a mediator of anti-inflammatory properties of human mesenchymal stromal cells, as well as of their survival pathways and their capability to home and migrate towards endocannabinoid sources. |
2014-09-11 |
2023-08-12 |
human |
| Daniel García-Ovejero, Ángel Arévalo-Martín, Beatriz Navarro-Galve, Emmanuel Pinteaux, Eduardo Molina-Holgado, Francisco Molina-Holgad. Neuroimmmune interactions of cannabinoids in neurogenesis: focus on interleukin-1β (IL-1β) signalling. Biochemical Society transactions. vol 41. issue 6. 2014-08-29. PMID:24256257. |
nscs express functional cb1 and cb2 cannabinoid receptors, daglα (diacylglycerol lipase α) and the nsc markers sox-2 and nestin. |
2014-08-29 |
2023-08-12 |
Not clear |
| Daniel García-Ovejero, Ángel Arévalo-Martín, Beatriz Navarro-Galve, Emmanuel Pinteaux, Eduardo Molina-Holgado, Francisco Molina-Holgad. Neuroimmmune interactions of cannabinoids in neurogenesis: focus on interleukin-1β (IL-1β) signalling. Biochemical Society transactions. vol 41. issue 6. 2014-08-29. PMID:24256257. |
we have investigated the role of cb1 and cb2 cannabinoid receptors in the control of nsc proliferation and in the release of immunomodulators [il-1β and il-1ra (il-1 receptor antagonist)] that control nsc fate decisions. |
2014-08-29 |
2023-08-12 |
Not clear |
| Daniel García-Ovejero, Ángel Arévalo-Martín, Beatriz Navarro-Galve, Emmanuel Pinteaux, Eduardo Molina-Holgado, Francisco Molina-Holgad. Neuroimmmune interactions of cannabinoids in neurogenesis: focus on interleukin-1β (IL-1β) signalling. Biochemical Society transactions. vol 41. issue 6. 2014-08-29. PMID:24256257. |
pharmacological blockade of cb1 and/or cb2 cannabinoid receptors abolish or decrease nsc proliferation, indicating a critical role for both cb1 and cb2 receptors in the proliferation of nsc via il-1 signalling pathways. |
2014-08-29 |
2023-08-12 |
Not clear |
| Monika Buraczynska, Piotr Wacinski, Pawel Zukowski, Michal Dragan, Andrzej Ksiaze. Common polymorphism in the cannabinoid type 1 receptor gene (CNR1) is associated with microvascular complications in type 2 diabetes. Journal of diabetes and its complications. vol 28. issue 1. 2014-08-27. PMID:24075694. |
endocannabinoids exert their biological effects via interaction with g-protein coupled cannabinoid receptors cb1 and cb2. |
2014-08-27 |
2023-08-12 |
human |
| Jenny L Wiley, Julie A Marusich, Timothy W Lefever, Megan Grabenauer, Katherine N Moore, Brian F Thoma. Cannabinoids in disguise: Δ9-tetrahydrocannabinol-like effects of tetramethylcyclopropyl ketone indoles. Neuropharmacology. vol 75. 2014-08-19. PMID:23916483. |
similar to other psychoactive cannabinoid agonists, xlr-11 and ur-144 showed low nanomolar (<30) affinity for cb1 and cb2 receptors, activated these receptors as full agonists, and produced dose-dependent effects that were blocked by rimonabant in mice, including antinociception, hypothermia, catalepsy and suppression of locomotor activity. |
2014-08-19 |
2023-08-12 |
mouse |
| Francisco Espejo-Porras, Javier Fernández-Ruiz, Roger G Pertwee, Raphael Mechoulam, Concepción Garcí. Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors. Neuropharmacology. vol 75. 2014-08-19. PMID:23924692. |
the broad presence of cb1 receptors in the basal ganglia, mainly in gaba- or glutamate-containing neurons, as well as the presence of trpv1 receptors in dopaminergic neurons and the identification of cb2 receptors in some neuronal subpopulations within the basal ganglia, explain the powerful motor effects exerted by those cannabinoids that can activate/block these receptors. |
2014-08-19 |
2023-08-12 |
rat |
| Francisco Espejo-Porras, Javier Fernández-Ruiz, Roger G Pertwee, Raphael Mechoulam, Concepción Garcí. Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors. Neuropharmacology. vol 75. 2014-08-19. PMID:23924692. |
by contrast, cannabidiol (cbd), a phytocannabinoid with a broad therapeutic profile, is generally presented as an example of a cannabinoid compound with no motor effects due to its poor affinity for the cb1 and the cb2 receptor, despite its activity at the trpv1 receptor. |
2014-08-19 |
2023-08-12 |
rat |
| Rebecca Hartzell Robinson, Joseph J Meissler, Jessica M Breslow-Deckman, John Gaughan, Martin W Adler, Toby K Eisenstei. Cannabinoids inhibit T-cells via cannabinoid receptor 2 in an in vitro assay for graft rejection, the mixed lymphocyte reaction. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology. vol 8. issue 5. 2014-08-18. PMID:23824763. |
cannabinoid receptor 2 (cb2) is expressed mainly on leukocytes and is the receptor implicated in mediating many of the effects of cannabinoids on immune processes. |
2014-08-18 |
2023-08-12 |
mouse |
| Rebecca Hartzell Robinson, Joseph J Meissler, Jessica M Breslow-Deckman, John Gaughan, Martin W Adler, Toby K Eisenstei. Cannabinoids inhibit T-cells via cannabinoid receptor 2 in an in vitro assay for graft rejection, the mixed lymphocyte reaction. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology. vol 8. issue 5. 2014-08-18. PMID:23824763. |
t-cell function was decreased by the cb2 agonists, as an elisa of mlr culture supernatants revealed il-2 release was significantly decreased in the cannabinoid treated cells. |
2014-08-18 |
2023-08-12 |
mouse |
| Ewa Kozela, Ana Juknat, Nathali Kaushansky, Neta Rimmerman, Avraham Ben-Nun, Zvi Voge. Cannabinoids decrease the th17 inflammatory autoimmune phenotype. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology. vol 8. issue 5. 2014-08-18. PMID:23892791. |
the downregulation of il-17 secretion by these cannabinoids does not seem to involve the cb1, cb2, pparγ, 5-ht1a or trpv1 receptors. |
2014-08-18 |
2023-08-12 |
mouse |
| Anna Maria Malfitano, Chiara Laezza, Giuseppe Saccomanni, Tiziano Tuccinardi, Clementina Manera, Adriano Martinelli, Elena Ciaglia, Simona Pisanti, Mario Vitale, Patrizia Gazzerro, Maurizio Bifulc. Immune-modulation and properties of absorption and blood brain barrier permeability of 1,8-naphthyridine derivatives. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology. vol 8. issue 5. 2014-08-18. PMID:24081326. |
considering the high selectivity at the cannabinoid cb2 receptor of recently designed 1,8-naphthyridine derivatives and the protective role of this receptor in neurological disorders, in this study we investigated the immune-modulatory and anti-inflammatory effects of these compounds as well as their potential properties of intestinal absorption and blood-brain barrier (bbb) permeability. |
2014-08-18 |
2023-08-12 |
Not clear |
| Jarogniew J Luszczki, Aleksandra Wlaz, Slawomir Karwan, Magdalena Florek-Luszczki, Stanislaw J Czuczwa. Effects of WIN 55,212-2 mesylate on the anticonvulsant action of lamotrigine, oxcarbazepine, pregabalin and topiramate against maximal electroshock-induced seizures in mice. European journal of pharmacology. vol 720. issue 1-3. 2014-08-15. PMID:24161913. |
the aim of this study was to determine the effect of win 55,212-2 mesylate (win - a non-selective cannabinoid cb1 and cb2 receptor agonist) on the protective action of four second-generation antiepileptic drugs (lamotrigine, oxcarbazepine, pregabalin and topiramate) in the mouse maximal electroshock seizure model. |
2014-08-15 |
2023-08-12 |
mouse |
| María S García-Gutiérrez, Antonio Ortega-Álvaro, Arnau Busquets-García, Jose M Pérez-Ortiz, Laura Caltana, María Jimena Ricatti, Alicia Brusco, Rafael Maldonado, Jorge Manzanare. Synaptic plasticity alterations associated with memory impairment induced by deletion of CB2 cannabinoid receptors. Neuropharmacology. vol 73. 2014-08-13. PMID:23796670. |
synaptic plasticity alterations associated with memory impairment induced by deletion of cb2 cannabinoid receptors. |
2014-08-13 |
2023-08-12 |
mouse |
| Shuxian Hu, Wen S Sheng, R Bryan Roc. CB2 receptor agonists protect human dopaminergic neurons against damage from HIV-1 gp120. PloS one. vol 8. issue 10. 2014-08-05. PMID:24147028. |
these data suggest that synthetic cannabinoids are capable of protecting human dopaminergic neurons from gp120 in a variety of ways, acting principally through the cb2 receptors and microglia. |
2014-08-05 |
2023-08-12 |
human |